1,25-Dihydroxyvitamin D3-mediated transforming growth factor-β release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiencies-Reference-Cited by-同舟云学术

1,25-Dihydroxyvitamin D3-mediated transforming growth factor-β release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiencies

Published:2009-12-03 Issue:3 Volume:11 Page:367-376
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Sterck Jozien G. H.,Klein-Nulend Jenneke,Burger Elisabeth H.,Lips Paul

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference45 articles.

1. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset;Kaufman;J Clin Endocrinol Metab,1992

2. Consequences of childhood-onset growth hor mone deficiency for adult bone mass;de Boer;J Bone Miner Res,1994

3. Reduced bone mineral density in patients with adult onset growth hormone deficiency;Holmes;J Clin Endocrinol Metab,1994

4. Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone deficient patients: dose response studies with biosynthetic human GH;Nielsen;Calcif Tissue Int,1991

5. Effects of 1,25-dihydroxyvitamin D3 and growth hormone therapy on serum osteocalcin levels in children with growth hormone deficiency;Antoniazzi;Bone Miner,1993

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged use of alendronate alters the biology of cranial repair in estrogen-deficient rats’ associated simultaneous immunohistochemical expression of TGF-β1+, α-ER+, and BMPR1B-;Clinical Oral Investigations;2017-12-02

2. Would Be Prophylactic Administrations of Low Concentration of Alendronate an Alternative for Improving the Craniofacial Bone Repair? A Preliminary Study Focused in the Period of Cellular Differentiation and Tissue Organization;Journal of Craniofacial Surgery;2017-10

3. Implementation of personalized medicine for fracture risk assessment in osteoporosis;Geriatrics & Gerontology International;2016-03

4. Association of Transforming Growth Factor β1 Genotype with Therapeutic Response to Active Vitamin D for Postmenopausal Osteoporosis;Journal of Bone and Mineral Research;2010-02-18

5. Cooperative effect of serum 25-hydroxyvitamin D concentration and a polymorphism of transforming growth factor-β1 gene on the prevalence of vertebral fractures in postmenopausal osteoporosis;Journal of Bone and Mineral Metabolism;2010-01-07